Next Article 
Molecular and Cellular Biology, November 2000, p. 8303-8318, Vol. 20, No. 22
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Selection of Alternative 5' Splice Sites: Role of
U1 snRNP and Models for the Antagonistic Effects of SF2/ASF and
hnRNP A1
Ian C.
Eperon,1,*
Olga V.
Makarova,1,
Akila
Mayeda,2,3
Stephen H.
Munroe,4
Javier F.
Cáceres,2,5
Daniel G.
Hayward,1 and
Adrian
R.
Krainer2
Department of Biochemistry, University of
Leicester, Leicester LE1 7RH,1 and MRC
Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU,
United Kingdom5; Cold Spring Harbor
Laboratory, Cold Spring Harbor, New York
11724-22082; Department of Biochemistry
and Molecular Biology, University of Miami School of Medicine,
Miami, Florida 33136-10193; and
Department of Biology, Marquette University, Milwaukee,
Wisconsin 532334
Received 26 May 2000/Returned for modification 13 July
2000/Accepted 24 August 2000
 |
ABSTRACT |
The first component known to recognize and discriminate among
potential 5' splice sites (5'SSs) in pre-mRNA is the U1 snRNP. However,
the relative levels of U1 snRNP binding to alternative 5'SSs do not
necessarily determine the splicing outcome. Strikingly, SF2/ASF, one of
the essential SR protein-splicing factors, causes a dose-dependent
shift in splicing to a downstream (intron-proximal) site, and yet it
increases U1 snRNP binding at upstream and downstream sites
simultaneously. We show here that hnRNP A1, which shifts splicing
towards an upstream 5'SS, causes reduced U1 snRNP binding at both
sites. Nonetheless, the importance of U1 snRNP binding is shown by
proportionality between the level of U1 snRNP binding to the downstream
site and its use in splicing. With purified components, hnRNP A1
reduces U1 snRNP binding to 5'SSs by binding cooperatively and
indiscriminately to the pre-mRNA. Mutations in hnRNP A1 and SF2/ASF
show that the opposite effects of the proteins on 5'SS choice are
correlated with their effects on U1 snRNP binding. Cross-linking
experiments show that SF2/ASF and hnRNP A1 compete to bind pre-mRNA,
and we conclude that this competition is the basis of their functional
antagonism; SF2/ASF enhances U1 snRNP binding at all 5'SSs, the rise in
simultaneous occupancy causing a shift in splicing towards the
downstream site, whereas hnRNP A1 interferes with U1 snRNP binding such
that 5'SS occupancy is lower and the affinities of U1 snRNP for the
individual sites determine the site of splicing.
 |
INTRODUCTION |
Alternative splicing of pre-mRNA is
responsible for the production of multiple mRNA and protein products
from individual genes. In many cases, different protein isoforms have
unique functions, and their production is tightly regulated at the
splicing level. Although a common form of alternative splicing involves
the omission or skipping of specific exons during splicing, there are
many examples of alternative splicing in which two or more alternative 5' splice sites (5'SSs) compete for joining to a single 3' splice site.
In such cases, both sites may be used ubiquitously, or their use may be
stringently regulated. Similarly, the deliberate introduction of a
duplicate 5'SS may result in use of either site or both sites, depending on the precise context, including the sequence of the sites,
their relative 5'-3' order, separation, adjacent sequences, or
secondary structures (9, 28, 31, 33, 46, 57, 58, 66, 73).
Some of these influences reflect the activity of trans-acting factors.
One trans-acting factor is the U1 snRNP, the RNA component
of which forms base pairs across the 5'SSs. The strength of base pairing correlates with the choice of 5'SSs in vivo, at least in some
circumstances (39, 77, 95), suggesting that a low probability of binding by U1 snRNP and different affinities for various
5'SSs can dictate 5'SS preferences. This idea is consistent with the observation in Saccharomyces cerevisiae that
interactions by components of the U1 snRNP with the cap-binding complex
or adjacent pre-mRNA sequences can influence 5'SS
selection (34, 71). However, this simple explanation is
contradicted in mammals by two sets of results: selective splicing with
duplicated sites and a poor correlation of splicing preferences with U1
snRNP binding in vitro (24, 58, 65, 66, 92). Ribonuclease H
protection assays have shown that two alternative consensus 5'SSs are
occupied simultaneously on each molecule of pre-mRNA by U1-dependent
complexes at the initial stages of a splicing reaction, even though
only one site (the downstream or intron-proximal site) is used for splicing (32). Thus occupation of one site does not affect
binding to another. This finding suggests a model in which U1 snRNP
particles bind independently to all alternative 5' splice sites, but
the splicing outcome depends on the numbers of sites occupied on each molecule; when the level of binding is low, then whichever site is
occupied at a critical point will be used, and the ratio of use depends
primarily on the affinity or probability of occupancy at each site
(which will depend on the sequence of the site and also other factors,
such as the flanking sequences, cap proximity, etc.); at the opposite
extreme, when multiple sites are occupied simultaneously by U1 snRNP
particles, the downstream site will be used (32, 68). This
model offers an explanation for some of the strong polarity effects
seen in 5'SS selection, without invoking any inherent polarity in 5'SS
complex formation.
After U1 snRNP binding, a 5'SS is incorporated into a commitment
complex (47, 60, 61, 78, 93). It is not known whether it is
at this stage that the downstream site is selected when U1 snRNP
particles are bound to several alternative sites on a molecule of
pre-mRNA. After formation of the spliceosome, U1 snRNA is displaced by
U6 snRNA (64). Surprisingly, the extent of U6 base pairing
to close alternative 5'SSs can determine preferences if there is a
sequence nearby to which U1 snRNA can form base pairs (39).
Similarly, there are circumstances in which base pairing of U5 snRNA
can affect alternative 5'SS preferences (27, 67). However,
in neither case is it clear whether the effect is of any significance
for the selection of competent alternative sites.
Other factors appear to be able to affect the choice of sites on the
basis of the position of the sites rather than their sequences. The
first proteins shown to affect splice site selection were the SR
proteins (36, 37, 43, 91). These proteins have one or two
RNA recognition motif (RRM)-type RNA-binding domains and a
characteristic C-terminal domain rich in SR or RS dipeptides (7). They generally stimulate splicing of either
constitutive or optional exons (reviewed in references 15, 52,
86), and at least some of their functions are mediated by
recognition of specific sequences in the exons (25, 45, 49-51,
59, 72, 74, 75, 82, 84, 85). The SR proteins affect the choice of
alternative 5' splice sites as well, and generally they stimulate use
of the downstream alternative site both in vitro (14, 22, 32, 37,
43, 54, 91, 96) and in vivo (16, 17, 62, 76, 87, 88,
94). Only p54, which is the most divergent family member, has
never been reported to cause a shift in splicing to the downstream 5'SS
but only to the upstream one (94).
The effect of most SR proteins on the selection of alternative 5'SSs
raises two important questions: do they, as with the inclusion of
exons, require specific recognition of sequences in the pre-mRNA, and
do they act via U1 snRNP redistribution on the alternative sites?
Although only a few substrates have been tested, some results indicate
that the effects of SRp20 (16, 76), SRp40, and SRp55
(91, 92) vary with the substrate. Interestingly, exon
enhancer sequences have been identified that do affect the choice of
alternative 5'SSs in caldesmon and adenovirus E1a pre-mRNA (11,
31). Based on the model for selection of 5'SSs by U1 snRNP,
described above, we predicted that SF2/ASF shifted splicing to the
downstream site because it tightened U1 snRNP binding indiscriminately,
increasing the proportion of pre-mRNA in which the alternative sites
were bound simultaneously. This prediction was confirmed by showing
that the protein did increase the number of pre-mRNA molecules in which
two alternative 5'SSs were occupied simultaneously in nuclear extract
(32). Further support for this model came from experiments
showing that SF2/ASF directly promoted U1 snRNP binding to a single
5'SS to form a ternary complex (41, 42). This activity
requires the C-terminal RS domain of SF2/ASF (41, 42).
However, the domain is not required for alternative splicing activity
(14, 16, 87, 96). The implication is that the alternative
splicing activity is not mediated by effects on U1 snRNP binding.
However, no other mechanisms have been proposed, and it is important to
reexamine the possibility that the result depended on the native gel
electrophoresis assay used.
The other major class of proteins shown to affect 5'SS selection
comprises the hnRNP A/B proteins. hnRNP A1, the best characterized member of the group, has activities including nucleocytoplasmic shuttling (69), a possible role in mRNA export (40,
81), and accelerating RNA annealing (21, 63, 70). The
proteins have two RRM-type RNA-binding domains and a C-terminal region rich in arginine and glycine. Like other hnRNP proteins, they bind
nascent RNA in vivo (30) and are components of the
nonspecific H complex that assembles on exogenous RNA in nuclear
extracts (6). The intrinsic specificity with which hnRNP A1
binds RNA is controversial (1, 2, 12); purified hnRNP A1
binds RNA cooperatively (21).
In pre-mRNA splicing, the hnRNP A/B proteins generally promote the use
of the 5'-most of two alternative 5'SSs and exon skipping both in vitro
and in vivo, counteracting SF2/ASF (17, 53-55, 79, 82, 90).
Whether these actions depend in general on the recognition of specific
sequences is an open question. In certain cases, it has been shown that
hnRNP A1 recognizes specific sites within an exon (19, 29)
or in flanking intron sequences (10, 23), as a prelude to
exon skipping. However, although the specific sites enhanced the effect
of exogenous hnRNP A1 on the use of alternative 5'SSs derived from the
hnRNP A1 pre-mRNA itself, they were not essential (10). An
extensive analysis of the effect of mutations in hnRNP A1 has shown
that the strengths of sequence-specific binding and annealing
activities are correlated with the ability of mutants to affect
alternative splicing of a
-globin-derived substrate but that the
alternative splicing activity is much more sensitive to the mutations,
i.e., that these activities of hnRNP A1 are insufficient for modulation
of 5'SS selection (55, 56).
In terms of the model based on U1 snRNP binding described above, the
effects of hnRNP A1 on 5'SS selection suggest that it might reduce
binding of U1 snRNP and thus the likelihood of simultaneous occupancy
of alternative 5'SSs. As a result, the use of specific sites would
depend on the individual probabilities that they are occupied, i.e., on
their affinity for U1 snRNP, rather than their position. Consequently,
we have tested the prediction that hnRNP A1 reduces U1 snRNP binding,
and we have determined the mechanisms of this effect. We conclude that
the effects of both SF2/ASF and hnRNP A1 are consistent with our model
and involve modulations of U1 snRNP binding to alternative 5'SSs,
shifting the balance between simultaneous and single occupancy of the
alternative 5'SSs on each molecule of pre-mRNA.
 |
MATERIALS AND METHODS |
Proteins and RNA.
hnRNP A1, SF2/ASF, and their mutants were
all prepared as recombinant proteins from Escherichia coli
as previously described (14, 26, 44, 54) and dialyzed
against buffer D. The proteins had no extraneous tags, except for
oligohistidine on the RRM1/RS and RRM2/RS mutant forms of SF2/ASF. U1
snRNP was generously supplied by B. Kastner, C. L. Will, and R. Luhrmann (4). HeLa nuclear extracts were supplied by 4C
(Mons, Belgium). C175G and AdML WW transcripts
have been described (32, 68); CE1a transcripts were derived
from pS10 (23); human
-globin sequences comprising exon
1, intron 1 (IVS-1), and part of exon 2 were transcribed from plasmid
3'D-205 (73). Mutants of AdML WW containing potential target
sites for hnRNP A1 were prepared by incorporating the sequence TAGGGCAGGC, from the K-SAM exon of the fibroblast growth
factor receptor 2 gene (29), between nucleotides 40 and 41 from the transcription start site (producing Ad 40), between
nucleotides 132 and 133 (producing Ad 132), and at both positions (Ad
40/132). Ad 40/132 contains an additional difference at position 125, which is T rather than C.
Splicing and psoralen cross-linking.
AdML transcripts were
prepared with m7G caps as previously described
(68). The final concentrations of components in the splicing
reaction mixtures were 0.4 mM ATP, 17 mM phosphocreatine, 2.7 mM
MgCl2, 1.8% (wt/vol) low-molecular-weight polyvinyl
alcohol (PVA), 33% nuclear extract, 2.5% (vol/vol) RNasin (Promega),
additional 17 mM HEPES-KOH (pH 7.5), 0.005% Tween 20, 33% (vol/vol)
buffer D or protein supplements, and AMT-psoralen (HRI) at 0.016 µg/µl. The protein concentrations were as noted in the figure
legends. Mixtures were preincubated at 30°C for an hour to permit
phosphorylation of SF2/ASF before pre-mRNA was added (38).
Cross-linking and quantification were performed as previously described
(68), using a PhosphorImager (Molecular Dynamics) and a
Cyclone (Canberra Packard) for measurements.
Ribonuclease H cleavage assays.
For kinetic assays,
incubations were done routinely in volumes of 15 µl, comprising U1
snRNP, hnRNP A1, or mutant proteins, at concentrations given in the
figure legends, C175G pre-mRNA, approximately
66% (vol/vol) buffer D [with 0.1 M KCl or 0.08 M potassium glutamate
(8)], 3.2 mM MgCl2, 20 mM phosphocreatine, 1.7 mM ATP, 1.7% (wt/vol) PVA, and 2.7% (vol/vol) Rnasin. In some experiments, 0.05% Nonidet P-40 (NP40) was included (80).
These were standard in vitro-binding conditions. Cleavage was initiated typically by addition to all reaction mixtures simultaneously of 5 to 8 µl containing 300 pmol of 14-mer oligodeoxyribonucleotide, 0.05%
NP40, and approximately 1 U of RNase H (Pharmacia) in buffer D. Samples
of 1 to 1.5 µl were withdrawn simultaneously from the reactions and
mixed with 50 µl of proteinase K digestion mixture on ice before
incubation, precipitation with ethanol, and gel electrophoresis.
Quantification of the extent of cleavage was done with a
PhosphorImager, correcting the signals for the numbers of labeled
nucleotides in the RNA. The simulations and fitting of reaction
kinetics were done with the program KfitSim.
Solid-phase assays.
For immobilization of U1 snRNP in
microtiter plates, 10-µl aliquots containing 1 µg of U1 snRNP in
the standard in vitro-binding buffer were incubated at 4°C in each
well of a high-protein-binding vinyl microtiter plate for 2 to 3 h. The wells were blocked for several hours with 2 mg of acetylated
bovine serum albumin (BSA) (Sigma) per ml in buffer D-0.05% NP40,
washed with the same buffer, and incubated at 30°C for 30 min in
standard in vitro-binding buffer with labeled pre-mRNA, SF2/ASF, or
hnRNP A1 at concentrations given in the figure legends and 2 mg of
acetylated BSA per ml. The unbound RNA was removed by washing with
buffer D-0.05% NP40 (and BSA in some experiments). For the experiment
summarized in Fig. 2B (see below), one set of wells was washed three
times in 1 min, a second set was washed five times in 5 min, and a
third set was washed seven times in 10 min. The residual RNA was
measured by scintillation counting. For RNase H cleavage of the 5' end of U1 snRNA (see Fig. 7A below), the unbound U1 snRNP was removed after
blocking, and then 10-µl portions of standard in vitro-binding buffer
were added to each well, containing 43 pmol of specific or arbitrary
oligonucleotide, 0.6 U of RNase H, and 2 mg of acetylated BSA per ml.
After 30 min at 30°C, wells were washed three times, and the RNA and
recombinant-protein components were added as above.
For recovery of U1 snRNP on immobilized RNA, labeled biotinylated
C175G RNA was incubated with M-280 streptavidin Dynabeads (Dynal) in buffer D-0.05% NP40, with 4 mg of acetylated BSA
per ml and RNasin. Three-microliter portions of the beads were
distributed among wells of a silanized microtiter plate; 15 µl of
standard binding buffer containing U1 snRNP (0.2 µg), 2 mg of BSA per
ml, and SF2/ASF at 0.5 µM was added to each well. In some cases, U1
snRNA was cleaved by RNase H in the buffer before the addition of
SF2/ASF and transfer to the beads. Bound U1 snRNP was detected by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
Western blotting, incubation with anti-Sm and anti-U1 A antibodies, and
enhanced chemiluminescence.
U1 snRNP was immobilized on nitrocellulose pieces, 6 mm by 2 mm, by
incubation of 0.5 µg of U1 snRNP in 5 µl of standard in vitro-binding buffer (lacking ATP and phosphocreatine) overnight at
4°C. Blocking was done with 5% milk (wt/vol) in buffer D-0.05% NP40-1.3% (vol/vol) RNasin at 4°C for 3 h. After washing, the pieces were incubated with 20 µl of the same standard binding buffer
containing the four transcripts and recombinant proteins. After
washing, the bound RNA was eluted in 80% formamide-2% SDS at 80°C
and loaded on a 5 to 20% discontinuous polyacrylamide denaturing gel
containing 0.1% SDS. The electrode buffer (Tris-borate-EDTA) also
contained 0.1% SDS.
Protein cross-linking.
The binding reactions in Fig. 6B and
C (see below) were done in 5 µl of standard in vitro-binding buffer
(without ATP or phosphocreatine). Each sample was irradiated for
30 s with a broad-wavelength UV source (SpotCure, UVP). After
RNase treatment, the samples were run on SDS-PAGE and transferred
electrophoretically onto nitrocellulose for phosphorimage analysis.
Other methods.
Incubation mixtures for
nitrocellulose-binding assays were set up with various volumes rather
than masses of macromolecules, and the active proportion of RNA was
estimated. The analysis of binding to partially hydrolyzed, end-labeled
RNA was done as previously described (5), with the
difference that the complexes were recovered on nitrocellulose filters,
and the RNA was eluted for analysis by gel electrophoresis.
 |
RESULTS |
SF2/ASF and hnRNP A1 alter 5'SS preferences, but neither causes
selective redistribution of U1 snRNP binding to 5'SS.
To determine
whether the effect of hnRNP A1 on alternative 5'SS selection is
associated with a general reduction in U1 snRNP binding, splicing
reactions were done with an AdML substrate (AdML WW) that has two
copies of the wild-type 5'SS (68). Splicing of this
substrate in nuclear extract responded as expected to both SF2/ASF and
hnRNP A1, with approximately threefold changes in the ratio of use of
the upstream and downstream sites (Fig. 1A, lanes 4, 8, and 12, and B).

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 1.
Effects of hnRNP A1 and SF2/ASF on selection of
alternative 5'SSs and U1 snRNP binding. (A) Splicing in vitro of AdML
WW in nuclear extract (NE) supplemented with SF2/ASF (SF2 [1.2 µM])
or hnRNP A1 (A1 [5.5 µM]) or both (SF2+A1). The splicing reaction
mixtures contained AMT-psoralen and were incubated for the times shown
(in minutes) above each lane before irradiation and electrophoresis of
a portion of each reaction on an 8% denaturing polyacrylamide gel. (B)
Ratios of splicing efficiency at the upstream (u/s) and downstream
(d/s) 5'SSs. The signals from u/s and d/s mRNA in panel A at 60 min
were measured, corrected for label incorporation, and expressed as the
ratios of the two isoforms of mRNA produced in each reaction. (C)
Analysis of U snRNA cross-links formed in the reactions. Portions of
the reactions in panel A were analyzed by electrophoresis on a 5%
denaturing polyacrylamide gel. (D) Abundance of the cross-linked
adducts. The intensities of the cross-linked U1 snRNA bands at 15 min
in panel C are shown as percentages of the pre-mRNA intensities and as
a ratio for the two sites; the ratio of the U6 cross-links is plotted
also. (E) Correlation between U1 snRNP binding and splicing at the
downstream (d/s) site. The graph shows on the ordinate the fraction of
splicing to the d/s site at 60 min (d/s mRNA/[u/s mRNA + d/s
mRNA]) versus the values for d/s U1 cross-links at 15 min (as in the
bar chart). Four points are derived from the experiment shown in panels
A and C; four others are derived from an independent experiment (not
shown).
|
|
The interactions of snRNA with the pre-mRNA substrate in these
splicing-reaction mixtures were detected by psoralen-mediated UV
cross-linking (Fig. 1C). The bands corresponding to U1 and U6 snRNA
cross-links to the alternative 5'SSs have been assigned (68). Their levels in the 15-min reactions (Fig. 1C, lanes
3, 7, 11, and 15) were measured and are shown in Fig. 1D as percentages of the level of the pre-mRNA. Comparisons between the levels of cross-linking at the upstream and downstream sites do not reveal the
relative levels of snRNA binding, because there appears to be an
intrinsic difference in cross-linking efficiency between the two sites,
but changes produced at each site or changes in the relative levels of
cross-linking at the sites in response to exogenous protein are informative.
Figure 1D shows that the levels of U1 snRNA cross-linking at both sites
were reduced by hnRNP A1. SF2/ASF addition increased cross-linking, as
expected (32, 42). Addition of both proteins produced little
change. The ratios of U1 snRNA cross-linking at the two sites did not
change in accord with splicing preferences (cf. Fig. 1B and D). In
contrast, the results for U6 snRNA suggested that its interactions are
selectively redistributed according to the pattern of splicing. Our
model for the role of U1 snRNP in splice site selection predicted that
the proportion of splicing from the downstream site would be
proportional to its occupancy by U1 snRNP, whereas splicing from the
upstream site would depend on the combined probability that it is
occupied and that the downstream one is not. To test the former
prediction, we plotted the proportion of splicing from the downstream
site at 60 min against the level of U1 cross-linking there at 15 min,
combining data from the experiment in Fig. 1A through D with data from
a separate but identical experiment (Fig. 1E). The result suggests very
strongly that use of the downstream site depends directly on the level
of U1 snRNP occupancy (R2 = 0.88). This
correlation is in striking contrast to the data for the upstream site;
its use decreased when cross-linking at both sites was increased by
SF2/ASF and increased when hnRNP A1 caused a reduction in
cross-linking.
hnRNP A1 directly reduces U1 snRNP binding to 5'SS.
To test
whether the effects of hnRNP A1 are mediated directly, we used an RNase
H cleavage assay to measure U1 snRNP binding to consensus 5' splice
sites. The substrate for these assays was C175G,
a
-globin pre-mRNA derivative with a consensus 5'SS 175 nucleotides
upstream of a natural 5'SS (32). Binding of U1 snRNP at the
consensus 5'SS protects the site against cleavage directed by an
oligonucleotide complementary to that site. The proportion of uncut
(protected) RNA in a reaction was measured. The consensus 5'SS was
protected by purified U1 snRNP (Fig. 2A, lane 1 versus lane 5), unlike a control site (lane 9 versus lane 13).
The presence of hnRNP A1 caused a marked reduction in protection (cf.
lane 3 with lane 1; 62% of the U1-dependent signal was lost), consistent with a loss of U1 snRNP binding or an enhanced rate of
dissociation. SF2/ASF reversed this effect (cf. lane 4 with lane 1),
suggesting that this simplified system might contain a sufficient
number of components to explain the known antagonistic effects of the
two proteins. Time-course analyses of RNase H cleavage confirmed that
the effect of hnRNP A1 on U1 snRNP-dependent protection could not be
caused by enhanced RNase H activity (data not shown; see below).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 2.
hnRNP A1 reduces binding of U1 snRNP to 5'SSs. (A)
Effects of hnRNP A1 and SF2/ASF on U1 snRNP-dependent protection of a
consensus 5'SS against RNase H cleavage. C175G
pre-mRNA was incubated with RNase H and purified U1 snRNP (0.035 µM),
recombinant hnRNP A1 (0.59 µM), or recombinant SF2/ASF (0.24 µM).
The components in each reaction are shown by shaded boxes above each
lane. Portions of each mixture were incubated for 15 min with one of
two cleavage oligonucleotides (sites of cleavage shown by arrows).
Reaction mixtures 1 through 8 were incubated with an oligonucleotide
complementary to a consensus 5'SS, which is protected by U1 snRNP
binding; reaction mixtures 9 through 16 were incubated with an
oligonucleotide complementary to an unprotected site. The diagrams at
the sides show the substrate, with black bars indicating the structure
of the RNA fragment in the corresponding position of the gel. (B)
Effects of hnRNP A1 and SF2/ASF on binding of RNA to and dissociation
from immobilized U1 snRNP. The labeled RNA retained (cpm) is plotted
against the approximate time of washing. Purified U1 snRNP was
immobilized in microtiter plate wells (ca. 1 µg per well) and
incubated in splicing buffer with 32P-labeled
C175G RNA and either hnRNP A1 or SF2/ASF at 0.5 µM. Parallel wells were treated identically but without U1 snRNP
[curves labeled ( )].
|
|
The effects of hnRNP A1 and SF2/ASF on interactions between U1 snRNP
and pre-mRNA were confirmed by a different assay. U1 snRNP was
immobilized in microtiter plate wells and incubated with
32P-labeled C175G pre-mRNA in the
presence or absence of either protein. The radioactivity retained was
measured after washing with buffer for various times (Fig. 2B). hnRNP
A1 approximately halved the amount of pre-mRNA retained. Strikingly,
SF2/ASF substantially increased the retention of pre-mRNA, confirming
the results of other assays (41, 42).
We conclude that hnRNP A1 reduces the binding of U1 snRNP to 5'SSs. The
effect is recapitulated by purified components and is therefore likely
to be direct.
Mutations in hnRNP A1 that blocked alternative splicing activity
also blocked its effects on U1 binding.
The preceding results
showed that hnRNP A1 can reduce the occupancy of 5'SSs by U1 snRNP. It
was not clear whether this effect caused the change in splicing
patterns, although it occurred when splicing was affected and was
predicted by our model. To test whether this property is sufficient for
hnRNP A1 to affect alternative 5'SS selection, mutant proteins that
lack alternative splicing activity were assayed to determine whether
any had retained the ability to reduce U1 snRNP binding. The same
mutants have been used to show that the activities of hnRNP A1 in
general RNA binding and annealing are not sufficient and may or may not
be necessary for alternative splicing function (55). The
results of multiple RNase H cleavage assays with purified U1 snRNP are
summarized in Fig. 3. All of the hnRNP A1
mutants lost much of their ability to reduce U1 snRNP binding; only one
(A1/RS, a chimera of the two RNA-binding domains of hnRNP A1 with the
RS domain of SF2/ASF) had any effect, but the reduction was very small
compared with that caused by wild-type hnRNP A1. In addition, two other
recombinant hnRNP A/B proteins were tested: hnRNP A1B, an
alternatively spliced isoform of hnRNP A1, and hnRNP A2, which is
encoded by a separate gene and is 70% identical to hnRNP A1. These
proteins have effects on 5'SS selection like that of hnRNP A1, although
the effect of hnRNP A1B is severalfold weaker
(55). Like hnRNP A1, both proteins allowed nearly complete
cleavage (cf. absence of U1 snRNP), but separate time course
experiments showed that hnRNP A1B and hnRNP B1 (an isoform
of hnRNP A2) affected U1 snRNP binding to a lesser extent than did
hnRNP A1 and A2 (data not shown). Thus, the results with both the
mutant forms of hnRNP A1 and the related proteins were consistent with
the hypothesis that the inhibition of U1 snRNP binding may be necessary
and sufficient for the effects of hnRNP A1 on alternative splicing.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 3.
hnRNP A1 mutants that are unable to affect alternative
splicing do not block U1 snRNP binding. C175G
pre-mRNA was subjected to RNase H digestion at the consensus 5'SS for a
fixed time after incubation in the presence of U1 snRNP (0.04 µM) and
either hnRNP A1, mutant proteins, or other hnRNP A/B proteins (1.0 µM). The proportion of uncut (protected) RNA in each case is
expressed relative to the high proportion protected by U1 snRNP in the
absence of hnRNP A1. The values shown are the means of 12 determinations in each case, and the error bars represent the standard
deviation. The proteins tested are represented to the right of the
chart. The two RRMs (boxed) and the Gly-rich C-terminal domain
(hexagon) are shown. X indicates mutations in the conserved RNP-1
submotif of an RRM; A1/RS contains the C-terminal RS domain of SF2/ASF
(hatched star) instead of the Gly-rich domain; A1-B is an alternatively
spliced variant of A1 with an insertion within the C-terminal domain.
|
|
hnRNP A1 blocked U1 snRNP association with the
pre-mRNA.
We considered three mechanisms for the effects of hnRNP
A1 on U1 snRNP interaction with 5'SSs: (i) the protein might bind to
the RNA and prevent U1 snRNP binding, (ii) it might bind U1 snRNP and
prevent it from binding, or (iii) it might interact with U1 snRNP-RNA
complexes and stimulate U1 snRNP dissociation.
We distinguished between mechanisms in which hnRNP A1 might prevent U1
snRNP binding (i and ii) and the mechanism in which it might stimulate
dissociation (iii) by measuring the rate of U1 snRNP dissociation via
time courses of digestion at a 5'SS by RNase H. The reaction can be
modeled as two first-order steps (slow U1 snRNP dissociation and fast
oligonucleotide annealing/cleavage), provided that the steps are
irreversible and that the two steps differ sufficiently in rate.
Irreversibility was tested as shown in Fig.
4A by the simultaneous addition of U1
snRNP and oligonucleotide (Fig. 4A, curve 5). This procedure produced a
cleavage curve almost identical to that produced in the absence of U1
snRNP (curve 6). Thus, U1 snRNP could not bind during cleavage, and its
dissociation would be irreversible under these conditions. Furthermore,
when cleavage was initiated after U1 snRNP was incubated with the RNA for 20 min (curve 4), the rate of cleavage was much slower. The rate
constant for U1 snRNP dissociation in a number of experiments was
calculated to be approximately 0.1 min
1, and for RNase H
cleavage it was typically around 1.2 min
1. The rate
constant for U1 snRNP dissociation was confirmed by a separate method,
in which U1 snRNP was incubated with C175G RNA in
the presence of psoralen; fresh binding was then blocked by the
addition of an oligonucleotide complementary to the 5' end of U1, and
dissociation was followed by irradiation of aliquots at intervals with
1-min pulses of UV light. A similar value was obtained (data not
shown). We concluded that the two steps are irreversible and differ
significantly in rate, satisfying the conditions for kinetic analysis.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 4.
HnRNP A1 does not facilitate U1 snRNP dissociation from
5'SSs or form stable complexes with U1 snRNP or pre-mRNA. Time courses
for oligonucleotide-directed RNase H cleavage at the consensus 5'SS in
C175G are shown, with the proportion of uncut RNA
plotted against the time of RNase H digestion. Components were
incubated for some or all of a 20-min period, as shown at the right of
the time courses, before RNase H cleavage was initiated by addition of
the oligonucleotide complementary to the 5'SS. (A) Effect of hnRNP A1
on U1 snRNP dissociation rates. U1 snRNP was present at 0.04 µM, and
hnRNP A1 was present at 1 µM. HnRNP A1 was added with the U1 snRNP
(curve 1), after 10 min (curve 2) or just before the cleavage
oligonucleotide was added (curve 3). U1 snRNP was added with the
oligonucleotide in one sample (curve 5). In this case, RNase H cleavage
was unaffected by the addition, indicating that the dissociation of U1
snRNP was irreversible once the oligonucleotides were added. (B)
Addition of unlabeled RNA to test whether hnRNP A1 forms stable
complexes with pre-mRNA or U1 snRNP. The components were added for the
times shown in the diagram. "RNA" is pre-mRNA; "tRNA" is yeast
tRNA. The final concentrations, before addition of the
oligonucleotides, were as follows: U1 snRNP, 0.04 µM; hnRNP A1, 0.5 µM; yeast RNA, 20 ng/µl.
|
|
To test whether hnRNP A1 affected the rate of dissociation, U1 snRNP
was allowed to bind to RNA for 20 min, and hnRNP A1 was added at
various times during this period before initiation of RNase H cleavage
of the 5'SSs by addition of the oligonucleotide. We observed that hnRNP
A1 had little effect on protection by U1 snRNP if added just before the
cleavage oligonucleotide (Fig. 4A, curve 3), although it almost
eliminated protection if added before the oligonucleotide (Fig. 4A,
curves 1 and 2). We conclude that hnRNP A1 has no significant effect on
the rate of dissociation of U1 snRNP but blocks its binding. In other
experiments, hnRNP A1 was shown to have a small effect if added 2 min
before the oligonucleotide (data not shown), the magnitude of this
effect being approximately as expected if it is assumed that hnRNP A1 blocks rebinding by the proportion of U1 snRNP that dissociates during
the 2-min period. We conclude that hnRNP A1 affects the binding rather
than the dissociation of U1 snRNP, and it is likely that this effect
involves either hnRNP A1 binding to the RNA or to U1 snRNP but not
specifically to the complex of the two.
hnRNP A1 did not block U1 snRNP binding by forming stable
complexes.
Chase experiments were done to test whether hnRNP A1
formed stable complexes with either the pre-mRNA (RNA) or U1 snRNP.
Pure hnRNP A1 was preincubated with either of these components, and then the missing component was added with yeast tRNA for a short time
before RNase H cleavage was initiated. The yeast tRNA had no effect on
U1 snRNP binding (Fig. 4B, curve 4; cf. curve 3) but blocked the effect
of hnRNP A1 (Fig. 4B, curve 2 versus curve 1). If hnRNP A1 formed
stable complexes with either component, before the free hnRNP A1 was
sequestered by the tRNA, then the hnRNP A1 effect would persist. When
hnRNP A1 was preincubated with U1 snRNP, the carrier tRNA eliminated
the hnRNP A1 activity (curve 2), and we inferred that the effect of
hnRNP A1 is not mediated via stable complexes with U1 snRNP. A small
effect was seen in some experiments when hnRNP A1 was preincubated with
C175G RNA (Fig. 4B, curve 6), but it was not
consistently observed. The reason for this variability may be that the
interactions of hnRNP A1 with RNA are very labile (UV laser
cross-linking showed that the bulk of hnRNP A1 dissociates from RNA in
seconds [I. C. Eperon and O. Makarova, unpublished data).
hnRNP A1 competed with U1 snRNP for binding to pre-mRNA.
Definitive evidence in favor of mechanism i, direct competition between
hnRNP A1 and U1 snRNP for binding to the pre-mRNA, could be achieved by
demonstrating that the effect of hnRNP A1 depends on the length of the
RNA. If hnRNP A1 formed an inactive complex with the snRNP, the length
of the target RNA would be irrelevant; if hnRNP A1 acted by binding to
the RNA, then, because binding to RNA is highly cooperative
(21), it ought to be much less effective at interfering with
U1 snRNP binding to 5'SSs on short RNA sequences. This prediction was
tested using as substrates C175G and a short RNA
of 15 nucleotides containing a consensus 5'SS. Preliminary experiments
with both psoralen cross-linking and RNase H assays showed that U1
binding to the shorter RNA was scarcely affected by hnRNP A1. However,
to eliminate variables it was necessary to test both substrates in the
same reaction and analyze the outcomes simultaneously. Several
different RNA sequences were incubated simultaneously with U1 snRNP
immobilized on nitrocellulose in the presence or absence of hnRNP A1.
The bound RNA was eluted and analyzed by electrophoresis on a
discontinuous denaturing gel. One of the RNA sequences contained no
high-affinity binding sites for U1 snRNP (AdML MM), and thus the
recovery of the other sequences could be expressed relative to it.
Results are shown in Fig. 5A and
quantified in Fig. 5B. U1 snRNP immobilized on nitrocellulose retained
preferentially the three RNA sequences containing 5'SSs (Fig. 5A, lanes
4 through 6 [cf. lanes 1 through 3]). The inclusion of hnRNP A1
blocked the U1-dependent retention of the two longer RNA sequences,
C175G and AdML CC, but the binding of the short
RNA was unaffected (lanes 10 through 12 [cf. lanes 4 through 6]). The
UP1 fragment of hnRNP A1 was used as a control for nonspecific effects
of RNA-binding proteins. UP1 has the RNA-binding domains of hnRNP A1
but no C-terminal domain, and it was shown earlier to have no effect on
U1 snRNP binding to 5'SS (Fig. 3). It had a smaller effect than hnRNP
A1 in this assay (Fig. 5A, lanes 16 through 18 versus 10 through 12).
Thus, hnRNP A1 acts more effectively to block U1 snRNP binding to 5'SSs
in long RNA substrates; this observation excludes mechanism ii, in
which hnRNP A1 would bind directly to U1 snRNP and sequester it, and it
also shows that hnRNP A1 does not act primarily by recognition of and
binding to 5'SSs. Instead, we infer that hnRNP A1 blocks U1 snRNP
binding as a consequence of binding to RNA either indiscriminately or
at specific sites away from the 5'SSs.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 5.
HnRNP A1 does not reduce binding of short 5'SS RNA to
immobilized U1 snRNP. Pieces of nitrocellulose were incubated with or
without 0.5 µg of U1 snRNP. After blocking and washing, the filters
were incubated in splicing buffer with four RNA sequences and either
hnRNP A1, UP1 (both at 0.5 µM), or no protein. Reactions were done in
triplicate. After washing, the RNA was eluted. (A) Analysis of the RNA
on biphasic denaturing gels of 5 and 20% polyacrylamide. AdML MM and
AdML CC were derived from AdML WW by mutation of the 5'SSs to
respectively prevent recognition or produce consensus sequences
(68). (B) Quantification of the results in panel A. The band
intensities were expressed relative to the intensity of the AdML MM RNA
in each lane, and the mean was determined for each set of triplicates.
The standard deviations are shown.
|
|
If hnRNP A1 were to require specific sequences other than 5'SSs for its
effect on U1 snRNP binding, the most probable reason would be that
sites for which it had high affinity nucleated cooperative binding. We
tested this by measuring hnRNP A1 binding to an RNA substrate known as
CE1a, a portion of the hnRNP A1 pre-mRNA that contains a site to which
hnRNP A1 binds specifically in nuclear extracts (23).
CE1a-based substrates were end labeled, subjected to partial
hydrolysis, and incubated with hnRNP A1. The bound RNA molecules were
recovered by nitrocellulose filtration and analyzed by gel
electrophoresis. Molecules of all lengths were retained, including
those that lacked the high-affinity site (data not shown). We conclude
that a specific site is not necessary for binding. Thus, cooperative,
nonspecific binding of hnRNP A1 to the RNA is the most likely mechanism
by which it interferes with the binding of U1 snRNP at 5'SS.
Molecular mechanisms for the antagonistic effects of SF2/ASF and
hnRNP A1 on alternative 5'SS selection.
SF2/ASF enhances U1 snRNP
binding, and its effects are antagonized by hnRNP A1. The enhancement
may require initial interactions with the pre-mRNA and then with U1
snRNP (41, 42). Since hnRNP A1 does not interact with
SF2/ASF (20) or U1 snRNP (I. C. Eperon, unpublished
observations), it is probable that its antagonistic effects arise from
its binding to pre-mRNA. The mechanism of action proposed in the
previous section for hnRNP A1 suggests two simple possibilities:
SF2/ASF might facilitate the binding of U1 snRNP by binding to the RNA
at a small number of specific sites, without serious disruption of the
hnRNP A1 complex, or it might bind more generally, displacing hnRNP A1
and perhaps opening up any interfering secondary or protein-mediated
structures in the RNA. These alternatives were tested with purified proteins.
The binding parameters of the individual proteins to
C175G were studied using RNase H protection,
nitrocellulose binding, and UV cross-linking. Incubation with SF2/ASF
protected pre-mRNA against RNase H at all sites tested (data not
shown), consistent with data from RNase T1 protection (41).
Nonspecific inhibition of enzyme activity was ruled out by controls in
which the oligonucleotide was preincubated with the RNA and the enzyme was preincubated with SF2/ASF. Binding affinities were measured by UV
cross-linking. The fractional saturation was determined and used to
prepare a Hill plot. The plot was nonlinear for SF2/ASF, with half
saturation at approximately 6 × 10
8 M protein (data
not shown). This result suggests that SF2/ASF binds to a range of sites
with different affinities. For hnRNP A1, the Hill plot was linear, with
n > 1, consistent with the expectation of positive
cooperativity, but half saturation was reached at about the same
concentration as with SF2/ASF. Chase assays (addition of unlabeled RNA
to equilibrium binding mixtures, followed by UV cross-linking at
various times [data not shown]) showed that most of the hnRNP A1
dissociated within 10 s, and dissociation was complete by 30 s. SF2/ASF dissociated more slowly, and about 30% of the complex could
not be exchanged.
If SF2/ASF binds to only a limited set of specific sites, while hnRNP
A1 binds promiscuously as described above, then both proteins in a
mixture of the two should bind RNA over a broad range of relative
concentrations. This prediction was tested by UV cross-linking of
C175G RNA (Fig.
6A). Increasing concentrations of SF2/ASF
displaced hnRNP A1, showing that the two proteins bound competitively
at all cross-linkable sites.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 6.
SF2/ASF and hnRNP A1 compete for binding to pre-mRNA.
(A) Cross-linking at equilibrium of proteins mixed in various
proportions to labeled C175G pre-mRNA. Each
10-µl reaction contained hnRNP A1 at 0.5 µM and SF2/ASF as
indicated. After UV irradiation and RNase digestion, samples were
analyzed by SDS-PAGE. The right panel shows the ratio of the signals
from the cross-linked proteins (y axis) at the different
SF2/ASF concentrations, compared with the molar ratios of the proteins
added to the RNA. (B) Lack of effect of a high-affinity site for hnRNP
A1 on competition for binding. Cross-linking was done with labeled CE1a
RNA, containing either a high-affinity site (UAGAGU) or one of
two mutant sites (UAGCGU and UAGCU). Reactions were in
5 µl with hnRNP A1 at 0.5 µM. (C) Reactions were done as in panel B
but with mutant SF2 RS.
|
|
To test whether a binding site with high affinity for hnRNP A1 alters
the outcome, the experiment was repeated with CE1a sequences (23). Two variants containing mutations known to affect the specific hnRNP A1-binding site were tested in parallel. The results showed that the site had little or no effect; 0.5 µM hnRNP A1 predominated compared with 0.1 µM SF2/ASF, but 1 µM SF2/ASF
replaced hnRNP A1 almost completely (Fig. 6B). To exclude artifactual
aggregation of the RNA with the unphosphorylated RS domain, the
experiment was repeated with SF2/ASF lacking the RS domain. However,
the result was the same (Fig. 6C). Thus, over a rather narrow
concentration range, SF2/ASF completely replaced hnRNP A1. We conclude
that there are two aspects to the mechanism of action of SF2/ASF;
binding to the pre-mRNA both antagonizes hnRNP A1 binding and
facilitates U1 snRNP binding.
The RS domain of SF2/ASF was not required for the enhancement of U1
snRNP binding to 5'SSs.
If SF2/ASF affects the polarity of 5'SS
selection by strengthening U1 snRNP binding to both sites, then mutants
of SF2/ASF that affect alternative splicing should still affect U1
snRNP binding. Gel mobility assays indicated that this prediction may not hold for proteins lacking the RS domain (41, 42).
Because binding assays based on gel electrophoresis may be affected by the net charge of the protein, this issue was reexamined with different
assays. Purified U1 snRNP was immobilized in microtiter plate wells and
incubated with 32P-labeled human
-globin pre-mRNA,
comprising the first intron and flanking sequences. This substrate was
used because the level of U1 snRNP binding to the weak 5'SS was low,
which increased the proportional response to SF2/ASF. The results (Fig.
7A) showed that the levels of RNA binding
to the U1 snRNP were enhanced considerably by the presence of SF2/ASF
and even more so by mutant derivatives that are active in alternative
splicing: FF-DD, in which two phenylalanine groups in the RNP-1 motif
in the first RNA-binding domain were changed to aspartate, and
RS,
in which the C-terminal RS domain was deleted (14). It was
possible that this effect was caused by RNA binding to the protein
which, in turn, had bound to U1 snRNP, and that it did not result from
the enhancement of U1 snRNA base-pairing interactions with the
-globin RNA. To test this possibility, immobilized U1 snRNP was
treated with oligonucleotides and RNase H before incubation with the
labeled RNA. As shown in Fig. 7B, the level of RNA bound was halved
when the oligonucleotide was complementary to the 5' end of U1 snRNA.
It is probable that at least half of the stimulation in binding
seen in the presence of SF2/ASF and the mutant proteins was produced by
an enhancement of U1-5'SS interactions. A further test was done by
binding biotinylated C175G RNA to
streptavidin-coated beads, followed by incubation with U1 snRNP,
recovery of the bound material, and detection of the U1 snRNP
polypeptides by Western blotting. The results show that binding of U1
snRNP was enhanced by SF2/ASF and mutant proteins (Fig. 7B). Most of
the binding was eliminated if the U1 snRNP was treated beforehand with
RNase H and an oligonucleotide complementary to the U1 snRNA but not if
it was treated with a control oligonucleotide. Additional controls were
done with two further mutants of SF2/ASF (RRM1/RS and RRM2/RS) in which
the first or second RNA-binding domains of SF2/ASF had been deleted (14, 16). The mutants bind RNA weakly but lack alternative splicing activity in vitro (14). As predicted, RNase H
cleavage assays showed that neither protein affected U1 snRNP binding, even when present at concentrations up to 15 µM (results not shown). We conclude that there is a good correlation between the abilities of
SF2/ASF mutants to promote alternative splicing and their abilities to
enhance U1 snRNP binding.

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 7.
Absence of the RS domain of SF2/ASF does not compromise
the enhancement of U1 snRNP binding to 5'SSs. (A) Effects of SF2/ASF
mutant proteins on binding of human -globin IVS-1 pre-mRNA to
immobilized U1 snRNP. (Left panel) U1 snRNP was immobilized in
microtiter plate wells and, after blocking and washing, incubated with
32P-labeled RNA in splicing buffer in the presence of
SF2/ASF proteins at 0.5 µM; reactions were done in triplicate, and
the mean value for labeled RNA retained was plotted, with the standard
deviations shown; control wells were treated identically, but U1 snRNP
was omitted during immobilization. (Right panel) Involvement of the 5'
end of U1 snRNA in the enhancement of RNA binding by SF2/ASF was
determined; reactions were done in triplicate, as above, but before
addition of the labeled RNA, the wells were treated with RNase H and
either an oligonucleotide complementary to the 5' end of U1 snRNA
( -U1 5' oligo) or an arbitrary control oligonucleotide. (B) Binding
of U1 snRNP to immobilized RNA was examined. (Left panel) U1 snRNP
(0.04 µM) and SF2/ASF proteins (0.5 µM) were incubated with
streptavidin-coated beads that had or had not been previously bound by
biotinylated C175G RNA; bound U1 snRNPs were
eluted and detected after SDS-PAGE by Western blotting with anti-Sm
antibodies. (Right panel) U1 snRNP was incubated with -U1 5' or
control oligonucleotides and RNase H before addition to the binding
mixtures; U1 snRNP was detected by both anti-Sm and anti-U1-A
antibodies; the U1 snRNP proteins detected are labeled; the light
additional bands are produced by cross-reactivity with the SF2/ASF
proteins.
|
|
hnRNP A1 high-affinity sites flanking a splice site redirected
splicing without a corresponding change in U1 snRNP binding.
The
binding studies with partially hydrolyzed CE1a RNA had shown that
high-affinity sites were not required for efficient binding of hnRNP
A1. Likewise, the same site did not reduce the displacement of hnRNP A1
by SF2/ASF (Fig. 6B). This was surprising in view of the effects of
such sites on splicing (10, 19, 23, 29). To test whether, in
nuclear extracts, such sites would enhance recruitment of hnRNP A1 and
magnify the effects of hnRNP A1 on 5'SS selection, we prepared
derivatives of AdML WW pre-mRNA in which the 10-nucleotide exon
repressor and hnRNP A1 target from the K-SAM exon of fibroblast growth
factor receptor 2 (29) were inserted into either or both of
two positions: between the cap and the upstream 5'SS (Ad 40) and/or
between the two 5'SSs (Ad 132). After UV irradiation of
psoralen-containing splicing reactions, splicing and cross-linking in
each reaction were measured as in Fig. 1. The results of UV irradiation
after incubation in splicing conditions for various times are shown in
Fig. 8A, and the effects of exogenous
hnRNP A1 on splicing preferences are shown in Fig. 8B.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 8.
Effects of high-affinity binding sites for hnRNP A1 on
splicing and U1 snRNP binding. (A) Derivatives of AdML WW containing
10-nucleotide hnRNP A1 target sites from the fibroblast growth factor
receptor 2 gene at position 40 or 132 or both positions were incubated
in splicing reaction mixtures supplemented where shown (shaded) with
SF2/ASF (1.2 µM) or hnRNP A1 (5.5 µM) or both. The reactions
contained AMT-psoralen and were irradiated after incubation for
approximately 2, 5, 15, or 60 min (left to right in each block of four
lanes). Samples were analyzed by electrophoresis on 5 and 8%
denaturing polyacrylamide gels. The portions of the 5% gel that
resolved the cross-linked adducts are shown. The asterisks above the
diagrams of the pre-mRNA show the sites of insertion of the target
sites. (B) Effects of hnRNP A1 on splicing efficiencies at the upstream
(u/s) and downstream (d/s) 5'SS. The signals from u/s and d/s mRNA in
the 60-min reactions (lanes 4, 12, 20, 28, etc., in panel A) were
measured and corrected for label incorporation, and they are shown both
separately, as percentages of the total RNA (pre-mRNA and splicing
intermediates and products) in the reaction and as the ratios of the
two. (C) Abundance of the cross-linked adducts of AdML WW and Ad
40/132. The intensities of the cross-linked U1 snRNA bands at 5 min in
panel A (lanes 2, 10, 50, and 58) are shown as percentages of the
pre-mRNA intensities and as a ratio for the two sites.
|
|
The insertion of the hnRNP A1 target sequence in Ad 40 had little
effect on splicing, with a reproducible but small decline in the use of
the upstream 5'SS (Fig. 8B, u/s mRNA). However, exogenous hnRNP A1 did
not increase use of this site, as in the original AdML WW, but reduced
it, so the added protein produced little or no shift in splicing. The
insertion in Ad 132, placing the hnRNP A1 target between the two 5'SSs,
produced a striking increase in use of the upstream 5'SS, but there was
once again a slight reduction in use of both sites when hnRNP A1 was
added and thus only a small upstream shift was seen. When the target sequence was present at both sites (Ad 40/132), there was a basal increase in use of the upstream 5'SS. However, the addition of hnRNP A1
reproducibly produced a marked drop in use of the upstream site and a
small increase in use of the downstream 5'SS, causing an overall shift
towards the downstream site. With Ad 40 and Ad 132, exogenous SF2/ASF
produced the expected decrease in use of the upstream site and an
increase in use of the downstream site (data not shown); with Ad
40/132, there was little change in upstream-site use and a small
increase in use of the downstream site, resulting in a downstream shift
in the ratio that was less marked than that produced by hnRNP A1.
The levels of cross-linking to U1 snRNA were quantified in these
reactions after incubation for 5 min. In all of the mutants, the
addition of SF2/ASF produced an increase in the levels of cross-linking
at both sites, whereas hnRNP A1 reduced the levels. The quantification
of levels with mutant Ad 40/132 was difficult because the cross-linked
bands were unusually diffuse in the presence of exogenous hnRNP A1
(Fig. 8A, lanes 57 through 64). Nonetheless, a comparison of the levels
of cross-linking to AdML WW and Ad 40/132 pre-mRNA (Fig. 8C) shows that
the opposite effects of hnRNP A1 on splicing of these two substrates
did not result from an unusual fall in U1 snRNP binding to the upstream
5'SS or an increase in binding to the downstream 5'SS of the mutant. We
conclude that the presence of a potential high-affinity-binding site
for hnRNP A1 reduced the efficiency of use of even the upstream site in the presence of exogenous hnRNP A1 and that, with two such sites flanking the upstream 5'SS, the shift away from that site did not
result primarily from a reduction in U1 snRNP binding but from
sequestration of the site from other components.
 |
DISCUSSION |
The roles of U1 snRNP in selection of alternative 5'SSs.
We
have proposed that spliceosome assembly generally incorporates the U1
snRNP-5'SS complex furthest downstream; when U1 snRNP-binding levels
are low, then the affinity of binding will determine the likelihood
that a site is occupied and used; when binding levels are higher and
more than one site is occupied, then the relative positions of the
sites determine the outcome (32). Proteins that affect
splicing patterns might do so, according to this scheme, without any
intrinsic specificity or polarity by affecting the balance between
these two conditions. We have shown previously that U1 snRNP-dependent
complexes can form simultaneously on two alternative consensus 5'SSs on
each molecule of pre-mRNA and that the levels of these complexes were
increased by exogenous SF2/ASF, which shifts splicing to the downstream
site (32). However, the RNase H cleavage assay used for
those experiments does not detect initial (U2-independent) complexes at
nonconsensus sites, and it is only an indirect assay of U1 snRNP
interactions. Thus, to test whether the model was informative for
modulation of splicing by hnRNP A1, we used psoralen-mediated
cross-linking in nuclear extracts instead.
The results of the cross-linking assays in Fig. 1C and D were
consistent with our model. At both alternative 5'SSs, SF2/ASF increased
U1 snRNA binding as expected (32, 42) and hnRNP A1 reduced
binding as predicted. The ratio of U1 snRNA binding to the two sites
did not change pro rata with the ratio of splicing. This result may be
taken either as being consistent with our model or as indicating that
U1 snRNP binding is irrelevant for selection; it is not consistent with
the simple view that U1 snRNP binds a single site on pre-mRNA and that
this site is used for splicing. There are two further ways in which the
results in Fig. 1 are informative. First, reduced levels of U1 snRNP
binding and a switch to selection based on affinity rather than
position would be expected to produce a shift in the ratio of U1 snRNA
binding towards the site that is used for splicing. The shift in U1
snRNA cross-linking in the presence of hnRNP A1 towards the upstream
site is consistent with this expectation. More striking support for our
model comes from the remarkable correlation in Fig. 1E between the
fraction of splicing at the downstream site and the level of U1 snRNA
cross-linking there. Correspondingly, there is a more-or-less inverse
correlation between U1 snRNA cross-linking to the upstream site and its
use for splicing. This result clearly supports our proposal that, if
the downstream site is occupied by U1 snRNP, it will be used for
splicing, whereas the upstream site will be used only when the
downstream one is vacant.
The link between 5'SS position and use has interesting implications. In
general, an upstream alternative site must have an intrinsically
greater affinity for U1 snRNP if it is to be used significantly. For
example, if two sites were used equally and the efficiency of removal
of an intron were close to 100%, then the probability of U1 snRNP
binding at the downstream site would be 50%, but at the upstream site
it would be 100%. This affinity depends on factors such as the
sequence of the 5'SS, absence of impeding secondary structure in the
pre-mRNA, proximity of enhancers, etc. The presence of the 5' cap or
upstream intron complexes may affect the affinity of binding to the
upstream site also (48), although other results suggest that
the cap interaction has indiscriminate effects (68). The
nature of the components that interact with the U1-5'SS complex
furthest downstream is still unknown. Our results with U6 snRNA
cross-linking (Fig. 1D) appear to show that it cross-links to one site,
i.e., after the site has been selected for splicing, but the
cross-links to the downstream site are very faint, and the
quantification is not reliable. Nonetheless, it seems likely that
selection involves the early complexes that link the 5'SS and branch
site (3).
There have been relatively few other attempts to determine the
mechanisms by which alternative 5'SSs are selected and by which SR
proteins or other alternative splicing factors might act. In an S100
extract (in which there was no U1 snRNP binding in the absence of added
SR protein), SRp40 was observed to promote splicing to an upstream site
in simian virus 40 pre-mRNA and to enhance U1 snRNA cross-linking there
(92). This appears to be a specific effect enhancing the
affinity at this site. Of more importance to our argument was the
finding that SRp30b enhanced binding at both sites but spliced mainly
from the downstream site. This finding is consistent with the model.
Psoralen cross-linking was used to investigate U1 snRNP binding to a
normal and a cryptic 5'SS in an adenovirus pre-mRNA (83).
Addition of SR protein increased cross-linking at both sites and
enhanced use of the downstream site (to 97%), in agreement with our
model. However, in extracts depleted of the U1-A protein, parallel
treatments increased U1 snRNA cross-linking at both sites, but use of
the downstream site increased only slightly, from 2 to 15%. This
result has been interpreted as being inconsistent with our model, in
that the response to SR addition was incomplete even though U1 snRNP
binding rose (86). However, we note that the 7-fold increase
in the level of U1 snRNP binding to the downstream site was matched by
a 7.5-fold increase in splicing there. The much reduced switch compared
with the native extract might be attributed to the much lower
proportion of pre-mRNA bound by U1 snRNA in the depleted extract,
although no figures for the proportions of pre-mRNA cross-linked were
given (83).
If our model for the mechanisms of splice site modulation by SF2/ASF
and hnRNP A1 is correct, then there ought to be a strong connection
between the activities of mutant or related proteins in alternative
splicing and their effects on U1 snRNP binding. We have tested this
with a comprehensive panel of hnRNP A1 mutations and several other
hnRNP A/B proteins. Overall, the correspondence is very good. For
SF2/ASF, previous work had shown that removal of the RS domain (
RS)
left its alternative splicing activity intact or even increased it
(14, 96) but abolished the protein's activity in
constitutive splicing and eliminated its ability to form a U1
snRNP-containing complex on native gels (41, 42). This last
result contradicts both our postulated mechanism for the action of
SF2/ASF and our results in Fig. 7, but the assays used were different.
The native gel electrophoresis assay did not detect a complex between
pre-mRNA and SF2/ASF, even though nuclease cleavage experiments showed
that guanines throughout the RNA were protected, and no complex of RNA
with U1 snRNP was detected in the absence of SF2/ASF. Thus, one
possible explanation of the results might be that the His-tagged
RS
mutant enhances binding but that the complex is too labile to be
detected by the electrophoresis assay. The full SF2/ASF protein might
have conferred sufficient stability inappropriately by RNA-bridged
interactions between the unphosphorylated SR domain and the U1 70K
protein (89), a possibility that can be excluded in the case
of our assays because the RS domain mutants were active. Indeed, it
appears from our results that an unphosphorylated RS domain of SF2/ASF may interfere with the protein's activity. A clearer understanding of
the role of the RS domain is unlikely to emerge until the structures and stoichiometries of the complexes on the pre-mRNA are characterized.
Mechanisms of action of hnRNP A1 and SF2/ASF.
We demonstrated
in Fig. 2 to 4 that purified hnRNP A1 can reduce U1 snRNP binding to
5'SS and that it does so by preventing binding. The results in Fig. 5
and other data (not shown) indicate that long pre-mRNA substrates are
more susceptible, which tends to argue against the possibility that
hnRNP A1 blocks by forming stable binary complexes with free U1 snRNP.
Although far-Western blots did suggest that hnRNP A1 could interact
with some U1 snRNP proteins, such interactions were not detected by
kinetic assays (Fig. 4B) or by a variety of other techniques. U2 and U4
(but not U1) snRNPs have been found to coimmunoprecipitate with hnRNP A1 in vitro (13), but the interactions involved were not
identified. Thus, we assume that the primary cause of the reduction in
U1 snRNP binding is competition for binding to the RNA.
The mechanism is not so clear for SF2/ASF, which might enhance U1 snRNP
binding either by forming a binary complex first with the U1 snRNP or
by binding to the RNA and recruiting U1 snRNP. The relatively high
stability of the SF2/ASF-RNA complex that we measured by UV
cross-linking and the ability of SF2/ASF to replace hnRNP A1 suggest
that SF2/ASF binds independently, possibly forming higher-order
interactions. This direct analysis of binding rates and the stability
of the complex is consistent with inferences from assays of splicing
after preincubation (18, 35) but not with inferences from
the formation of gel-resistant U1 complexes (41). How the
complex accommodates U1 snRNP is unclear, particularly given that the
purine-rich sites preferred by the purified protein can include the
actual 5'SS (97). The properties of SF2/ASF may be affected
by phosphorylation in vivo or after incubation in nuclear extracts
(38), but the effectiveness of the
RS mutant in enhancing
U1 snRNP binding to 5'SS and in competing with hnRNP A1 for binding to
pre-mRNA demonstrates that these fundamental properties of SF2/ASF are
not artifacts of an unphosphorylated RS domain.
The binding properties of the purified proteins seem at first to be
incompatible with the observations of preferred sites of action in
extracts or in vivo. Our results suggest that purified hnRNP A1 binds
extensively in the absence of SELEX consensus sequences; SF2/ASF
competes for binding to most or all of the pre-mRNA. Our current
understanding suggests a model such as that shown in Fig. 9A. The diagram shows that the
specificity is not stringent; the range of affinities of each protein
for various sequences is quite narrow, and thus the proteins compete
for binding to virtually all sequences on the pre-mRNA. In a nuclear
extract or in vivo, there will be far more competing proteins, and the
proportion of the pre-mRNA occupied by any given protein is likely to
be smaller. Nonetheless, changes in the relative abundance of the proteins are likely to have significant consequences for the range of
sites bound by each protein. The diagram illustrates the effect of
SF2/ASF and hnRNP A1 concentrations upon U1 snRNP binding, based on the
model described and validated above. It is not yet clear whether
preferred SF2/ASF sites do need to be close to the 5'SS, as suggested,
but the diagram shows a site of high affinity near the upstream 5'SS
for the reasons explained above.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 9.
Models for the molecular mechanisms by which hnRNP A1
and SR proteins affect 5'SS selection. (A) The top panel shows
hypothetical binding sites of various affinities for two proteins on a
pre-mRNA containing two alternative 5'SSs. The distributions take
account of the fact that the proteins have marked sequence preferences
and yet appear to be able to occupy all available sites on the RNA at
concentrations used in alternative splicing assays in vitro. hnRNP A1
is shown to bind in a more regular fashion because of its
cooperativity. The affinity of interaction at each site is indicated by
a range from + to +++++. The middle panel depicts a possible
binding pattern in nuclear extract at a high concentration of SF2/ASF.
The high-, middle-, and low-affinity sites for SF2/ASF are occupied by
SF2/ASF protein (small circles), although hnRNP A1 (among other
proteins) competes for binding (crescent shape) and excludes SF2/ASF
from the latter's lowest-affinity sites. Thus, both splice sites are
close to a sequence bound by SF2/ASF, and U1 snRNP binding is enhanced
by interactions (double-headed arrow) at both sites. Double occupancy
leads to use of the downstream site. Double occupancy also results even
at normal concentrations of SF2/ASF if the 5'SSs have the consensus
sequence, because U1 snRNP binding outcompetes hnRNP A1. The lower
panel illustrates the effect of elevated hnRNP A1 concentrations. Only
at the highest-affinity sites can SF2/ASF or other SR proteins bind in
preference to hnRNP A1. U1 snRNP binding is reduced by competition with
hnRNP A1, and so double occupancy of the 5'SSs is unlikely. Thus,
splicing reflects the probability of occupancy of the individual sites.
In this case, the upstream site is favored because it is close to a
high-affinity site for SF2/ASF, permitting some U1 snRNP binding. The
equilibrium between hnRNP A1, SF2/ASF, and U1 snRNP at the downstream
site is dynamic, and, on molecules in which U1 snRNP bound initially at
the upstream 5'SS, it would be expected that U1 snRNP would also bind
eventually to the downstream site. By this time, the upstream site
might be committed to splicing. This may account for the observation of
a slower rate of nonproductive and cap-independent U1 snRNP binding to
unused sites (68). (B) The introduction of two high-affinity
binding sites (+++++) for hnRNP A1 resulted in an inversion of the
normal effects of hnRNP A1 on alternative splicing. Although the shift
to the downstream 5'SS was akin to the effect of SF2/ASF, the
reductions in U1 snRNP cross-linking at both 5'SSs and the results with
the individual high-affinity sites showed that the mechanism is quite
different. We propose that the two sites flanking the upstream 5'
splice site allow it to be inactivated when hnRNP A1 is elevated,
either because they mark out a domain for unusually stable cooperative
hnRNP A1 binding (patterned hnRNP A1 proteins) or because two bound
sites form a stable interacting complex that mitigates against
splicing. U1 snRNP occupancy at the downstream site would be low,
because of competition with hnRNP A1, but this site would be used
eventually. U1 snRNP may bind also to the upstream site, but the
sequestered site is unable to interact with other components. It is not
known whether the cooperative binding of hnRNP A1 is propagated in both
directions along the RNA or is unidirectional.
|
|
Figure 9A does not show any high-affinity sites for hnRNP A1.
Preliminary results with the hydrolysis assay showed that the SELEX
consensus target for hnRNP A1 in CE1a was not required for binding.
However, molecules containing the site were bound slightly more
efficiently, particularly with higher ratios of protein to RNA and in
the absence of competitor RNA. Although further experiments are
required, a possible interpretation is that a single occupied high-affinity site has little effect on binding, because the overall probability of a molecule of RNA being bound anywhere by protein is
scarcely affected, until a second molecule of hnRNP A1, bound elsewhere
on the same RNA molecule, interacts with it, and a conformational change produces a stable complex. Two potential high-affinity sites
would be more potent, on this basis, because the chance of simultaneous
occupancy and collision would be higher. The results of our splicing
assays with high-affinity sites (Fig. 8B) can be interpreted in this
light. Single K-SAM repressor sites seem to reduce the use of the
nearest downstream 5'SS, possibly by competition with adjacent SR
protein-binding sites. In the case of Ad 40, this effect might weaken
the ability of the upstream site to recruit U1 snRNPs in the face of an
increased concentration of hnRNP A1. The effects of the double
insertion suggest that the upstream 5'SS was sequestered between the
two sites in a proportion of the pre-mRNA when the concentration of
hnRNP A1 was raised. This effect is consistent with studies on hnRNP A1
pre-mRNA (10), and two possible mechanisms, one based on
that work, are shown in Fig. 9B. The observation that hnRNP A1 actually
has less effect on U1 snRNP binding to the sequestered site than the
site used for splicing (Fig. 8C), while tentative, inclines us to favor the lower model and is consistent with results on U1 snRNP binding reported for hnRNP A1 pre-mRNA (10). We have not yet
established that these sites are bound in extracts by hnRNP A1.
In summary, the present experiments offer substantial support for our
model of the roles of U1 snRNP in 5'SS selection, and this model
provides a good general framework for explaining the effects of hnRNP
A1 and SF2/ASF on 5'SS selection. Competition between these proteins
for binding to the pre-mRNA is likely to determine the outcome of U1
snRNP binding and thus splicing. Studies of the distribution and
dynamics of binding by these and other proteins under splicing
conditions should be a high priority for future studies.
 |
ACKNOWLEDGMENTS |
We are very grateful to Reinhard Lührmann, Berthold
Kastner, and Cindy Will for the generous gifts of purified U1 snRNP; Gideon Dreyfuss, David Williams, Silvano Riva, and Iain Mattaj for
antibodies; Benoit Chabot for clones containing CE1a sequences; Clive
Bagshaw for advice on the use of the program KfitSim; and Evgeny
Makarov for advice and criticism.
This research was supported by the Medical Research Council (United
Kingdom) and the Wellcome Trust (to I.C.E.) and in part by National
Cancer Institute grant CA13106 (to A.R.K.). The Wellcome Trust
supported the purchase of a PhosphorImager and a Cyclone imager.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biochemistry, University of Leicester, Leicester LE1 7RH, United
Kingdom. Phone: 44 116 2523482. Fax: 44 116 2523369. E-mail:
eci{at}le.ac.uk.
Present address: Max-Planck-Institut fur Biophysikalische Chemie,
Abt. Zellulare Biochemie, 37077 Gottingen, Germany.
 |
REFERENCES |
| 1.
|
Abdul-Manan, N.,
S. M. O'Malley, and K. R. Williams.
1996.
Origins of binding specificity of the A1 heterogeneous nuclear ribonucleoprotein.
Biochemistry
35:3545-3554[CrossRef][Medline].
|
| 2.
|
Abdul-Manan, N., and K. R. Williams.
1996.
hnRNP A1 binds promiscuously to oligoribonucleotides: utilization of random and homo-oligonucleotides to discriminate sequence from base-specific binding.
Nucleic Acids Res.
24:4063-4070[Abstract/Free Full Text].
|
| 3.
|
Abovich, N., and M. Rosbash.
1997.
Cross-intron bridging interactions in the yeast commitment complex are conserved in mammals.
Cell
89:403-412[CrossRef][Medline].
|
| 4.
|
Bach, M.,
P. Bringmann, and R. Luhrmann.
1990.
Purification of small nuclear ribonucleoprotein particles with antibodies against modified nucleosides of small nuclear RNAs.
Methods Enzymol.
181:232-257[Medline].
|
| 5.
|
Beck, J., and M. Nassal.
1996.
A sensitive procedure for mapping the boundaries of RNA elements binding in vitro translated proteins defines a minimal hepatitis B virus encapsidation signal.
Nucleic Acids Res.
24:4364-4366[Abstract/Free Full Text].
|
| 6.
|
Bennett, M.,
S. Piñol-Roma,
D. Staknis,
G. Dreyfuss, and R. Reed.
1992.
Differential binding of heterogeneous nuclear ribonucleoproteins to mRNA precursors prior to spliceosome assembly in vitro.
Mol. Cell. Biol.
12:3165-3175[Abstract/Free Full Text].
|
| 7.
|
Birney, E.,
S. Kumar, and A. R. Krainer.
1993.
Analysis of the RNA-recognition motif and RS and RGG domains: conservation in metazoan pre-mRNA splicing factors.
Nucleic Acids Res.
21:5803-5816[Abstract/Free Full Text].
|
| 8.
|
Black, D. L.
1992.
Activation of c-src neuron-specific splicing by an unusual RNA element in vivo and in vitro.
Cell
69:795-807[CrossRef][Medline].
|
| 9.
|
Blanchette, M., and B. Chabot. |